DeepMed Research

Peking University First Hospital (Peking Univesity First Medical School)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

China STEMI Care Project

Conditions: ST-Elevation Myocardial Infarction

Interventions: Other: in-hospital process optimization
Other: the whole-city STEMI care network construction
Other: PPCI hospital-based regional STEMI transfer network construction

First Posted Date: 2019-01-29

Last Posted Date: 2019-01-29

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 50000

Registration Number: NCT03821012

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Effect of Food on Pharmacokinetics of Salvianolic Acid A in Healthy Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: salvianolic acid A

First Posted Date: 2019-01-02

Last Posted Date: 2019-01-02

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 14

Registration Number: NCT03791463

Locations: 🇨🇳
Xiaocong Pang, Beijing, China

Phase I Single-dose Escalation Clinical Trial of Salvianolic Acid A Tablets

Phase 1

Conditions: Neuropathy of Diabetes

Interventions: Drug: Placebo Oral Tablet
Drug: Salvianolic Acid A

First Posted Date: 2019-01-02

Last Posted Date: 2019-01-02

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 40

Registration Number: NCT03791125

Locations: 🇨🇳
Department of Pharmacy, Base for Clinical Trial, Peking University First Hospital, Beijing, Beijing, China

Combination of Hypofractionated Proton Therapy With Immunotherapy

Phase 1

Conditions: Immunotherapy
Proton Therapy

Interventions: Combination Product: Radiation+PD-1 Ab

First Posted Date: 2018-12-05

Last Posted Date: 2018-12-05

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 30

Registration Number: NCT03764787

Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer

Phase 1

Conditions: Proton Therapy
Immunotherapy
Neoplasm Metastasis

First Posted Date: 2018-12-05

Last Posted Date: 2018-12-05

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 30

Registration Number: NCT03765190

Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block

Phase 4

Suspended

Conditions: Elderly
Knee Arthroplasty
Nerve Block
Dexmedetomidine
Postoperative Delirium
Long-term Outcome

Interventions: Drug: Placebo
Drug: Dexmedetomidine

First Posted Date: 2018-08-14

Last Posted Date: 2022-04-26

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 736

Registration Number: NCT03629483

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China

Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery

Not Applicable

Recruiting

Conditions: Coronary Artery Bypass, Off-Pump
Intraoperative Hypotension
Intraoperative Care
Acute Kidney Injury
Preventive Medicine

Interventions: Drug: Targeted blood-pressure management
Drug: Routine blood-pressure management

First Posted Date: 2018-08-14

Last Posted Date: 2023-05-31

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 612

Registration Number: NCT03629418

Locations: 🇨🇳
Beijing University First Hospital, Beijing, Beijing, China

Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery

Phase 4

Conditions: Elderly
Orthopedic Surgery
Analgesia
Dexmedetomidine
Postoperative Delirium
Long-term Outcome

Interventions: Drug: Placebo
Drug: Dexmedetomidine

First Posted Date: 2018-08-14

Last Posted Date: 2021-07-07

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 712

Registration Number: NCT03629262

Locations: 🇨🇳
Beijing Jishuitan Hospital, Beijing, China
🇨🇳
Peking University First Hospital, Beijing, China

A Multi-center Prospective Cohort Study Based on Peritoneal Dialysis Telemedicine-assisted Platform

Recruiting

Conditions: Peritoneal Dialysis

First Posted Date: 2018-06-27

Last Posted Date: 2023-10-25

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 7000

Registration Number: NCT03571451

Locations: 🇨🇳
The second affiliated hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳
Pingdingshan People's Hospital No.1, Pingdingshan, Henan, China
🇨🇳
First affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China

and more 24 locations

A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers

Not Applicable

Conditions: Liver Fibrosis
Hepatitis B

Interventions: Drug: Entecavir 0.5 mg
Drug: Anluohuaxian Pill 12g

First Posted Date: 2018-06-26

Last Posted Date: 2018-06-27

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 450

Registration Number: NCT03568578

Locations: 🇨🇳
Guiqiang Wang, Beijing, Beijing, China
🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy